C
Charles H. Hennekens
Researcher at Harvard University
Publications - 439
Citations - 120693
Charles H. Hennekens is an academic researcher from Harvard University. The author has contributed to research in topics: Risk factor & Relative risk. The author has an hindex of 150, co-authored 424 publications receiving 117806 citations. Previous affiliations of Charles H. Hennekens include University of Auckland & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
Prospective Study of Cataract Extraction and Risk of Coronary Heart Disease in Women
Frank B. Hu,Susan E. Hankinson,Meir J. Stampfer,JoAnn E. Manson,Graham A. Colditz,Frank E. Speizer,Charles H. Hennekens,Walter C. Willett +7 more
TL;DR: Findings are compatible with current hypotheses relating oxidative damage and tissue aging to the development of cataract and CHD.
Journal ArticleDOI
A case-control study of regular aspirin use and coronary deaths.
TL;DR: These data provide no evidence for a preventive role of regular aspirin intake in coronary deaths and even after controlling for possible confounding effects of other variables using a paired multiple logistic regression analysis, there was no evidence of association.
Journal ArticleDOI
Antioxidants and age-related eye disease. Current and future perspectives.
TL;DR: In this paper, the authors show that antioxidants can protect against the cumulative effects of oxidative stress in animal models of cataract and macular degeneration, but the results from several studies, primarily cross-sectional and case-control, are compatible with a possible protective role for micronutrients in disease development.
Journal ArticleDOI
Smoking Cessation and Time Course of Decreased Risks of Coronary Heart Disease in Middle-Aged Women
Ichiro Kawachi,Graham A. Colditz,Meir J. Stampfer,Walter C. Willett,JoAnn E. Manson,Bernard Rosner,Frank E. Speizer,Charles H. Hennekens +7 more
TL;DR: Women who stop smoking will experience an immediate benefit as well as a further longer-term decline in excess risk of coronary heart disease to the level of those who never smoked during the interval 10 to 14 years following cessation.
Journal ArticleDOI
Aspirin Use and Cognitive Function in the Elderly
TL;DR: Although no substantial effect was observed, the data are compatible with a modest benefit of aspirin, especially with intermittent use, on decline of cognitive function and concern about small residual biases from self-selection or confounding suggests that randomized trials will be necessary to provide definitive data on this question.